Background Direct comparisons of the tolerability and safety of migraine preventive
treatments targeting the calcitonin gene-related peptide pathway are lacking. This study …

Calcitonin gene-related peptide-targeted monoclonal antibodies (CGRP mAbs) are
increasingly being used as preventive treatments for migraine. Their effectiveness and …

Background Clinical trials and real-world studies revealed a spectrum of response to CGRP
(-receptor) monoclonal antibodies (mAbs) in migraine prophylaxis, ranging from no effect at …

Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs.
Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of …

Background Monoclonal antibodies against calcitonin gene-related peptide (CGRP) or its
receptor (anti-CGRP (-R) mAbs) and small-molecule CGRP receptor antagonists (gepants) …

The monoclonal antibodies (mAbs) blocking the calcitonin-gene related peptide (CGRP)
pathway, collectively called here “anti-CGRP/rec mAbs”, have dramatically improved …

Background Calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) are
approved in Europe as preventive treatment of migraine in patients with at least four monthly …

Background Erenumab has demonstrated effectiveness for prevention of migraine attacks,
but the treatment is costly, and a considerable proportion of patients do not respond to it. The …

Background Real-world data are accumulating on the effectiveness, tolerability and safety of
anti-calcitonin gene-related peptide pathway monoclonal antibodies for the preventive …

Background Controlled and real-world evidence have demonstrated the efficacy of
calcitonin gene related peptide (CGRP) monoclonal antibodies (MABs) in migraine …